Asia Pacific Medical Cyclotron Market

The medical cyclotron market in Asia Pacific is expected to grow from US$ 42.62 million in 2022 to US$ 72.18 million by 2028; it is estimated to register a CAGR of 9.2% from 2022 to 2028.

Nuclear medicine is a highly specialized area that develops and uses instruments and radiopharmaceuticals to investigate the physiological processes of patients and diagnose diseases noninvasively. Nuclear medicines are used to cure diseases, including different types of cancer, heart disease, psychiatric conditions, and gastrointestinal diseases. These medicines can be used to diagnose several disorders that require surgery, biopsy, or other invasive diagnostic tests. The introduction of advanced devices with a built-in shield and technological compatibility with positron emission tomography (PET) and single-photon emission computerized tomography (SPECT) devices is responsible for an increase in the acceptability of these devices. The rising acceptability of cyclotrons is likely to boost the market growth. Moreover, the high prevalence of cardiovascular diseases (CVDs) propels the market for nuclear medicines. Targeted treatments for a particular disease are easy to implement in clinics, and high efficacy and lesser side effects of the molecular imaging approach are the main advantages of personalized medicines. Further, thyroid cancer is one of the most common types of cancer that is either diagnostic or therapeutic. Molecular imaging plays an important role in the diagnosis and treatment of thyroid cancer as it aids visual representation, classification, and quantification of biological characteristics of cells and tissues in patients; using this method, healthcare providers can also provide personalized health management. Thus, the results of multimodal nuclear imaging could be used to develop a lesion-based strategy for patients with multiple heterogeneous metastatic lesions, which is driving the growth of the medical cyclotrons market in Asia Pacific.

Asia Pacific Medical Cyclotron Market Revenue and Forecast to 2028 (US$ Million)

Asia Pacific Medical Cyclotron Market Segmentation    

The Asia Pacific medical cyclotron market is segmented into type, capacity, end user, and country. Based on type, the market is bifurcated into ring cyclotron and azimuthally varying fields (AVF). The ring cyclotron segment held the larger share of the market in 2022. Based on capacity, the market is segmented into 10-12 MeV, 16-18 MeV, 19-24 MeV, and 24 MeV and above. In 2022, the 16-18 MeV segment held the largest share of the market. Based on end user, the market is categorized into hospitals, specialized clinics, pharmaceutical companies, and others. In 2022, the hospitals segment held the largest share of the market. Based on country, the Asia Pacific medical cyclotron market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Further, China held the largest share of the market in 2022.

A few of the key players operating in the Asia Pacific medical cyclotron market are Advanced Cyclotron Systems; Best ABT Molecular Imaging, Inc; Best Cyclotron Systems, Inc.; General Electric Company; IBA; Ionetix Corporation; isoSolution Inc.; Siemens AG; and Sumitomo Heavy Industries, Ltd.